Stock events for Incyte Corp. (INCY)
Over the past six months, Incyte's stock price has increased by 38.63%. As of October 2, 2025, the stock reached a new 52-week high of $88.66, trading at $87.39. The share price as of September 22, 2025, was $84.73, representing a 32.14% increase from September 23, 2024. Analyst ratings for Incyte are mixed, with a consensus "Hold" rating and an average target price of $83.64. Several research firms have recently adjusted their price targets. Insider activity has shown both buying and selling. Over the last three months, insiders bought 261.8K shares for a value of $15.7M and sold 21.6K shares for $1.4M. Incyte announced an additional FDA approval of Opzelura® Cream in children aged 2-11 with atopic dermatitis on September 18, 2025. The company also reported an inducement grant under Nasdaq Listing Rule 5635(c)(4) on September 24, 2025, and announced the appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer on September 22, 2025.
Demand Seasonality affecting Incyte Corp.’s stock price
Information regarding specific demand seasonality for Incyte Corp.'s products and services was not found in the provided search results. As a biopharmaceutical company focused on chronic conditions, demand for its products is generally driven by disease prevalence, diagnosis rates, and treatment guidelines rather than seasonal fluctuations. The consistent need for these treatments suggests a relatively stable demand throughout the year, rather than pronounced seasonality.
Overview of Incyte Corp.’s business
Incyte Corp. is a global biopharmaceutical company focused on discovering, developing, and commercializing therapeutics primarily in oncology, inflammation, and autoimmunity. Its core business segments are oncology, dermatology, and inflammation. The company's flagship product, Jakafi, is a first-in-class JAK1/JAK2 inhibitor approved for treating myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease and has been a significant revenue driver. Other major products include Pemazyre for unresectable biliary tract cancer, Monjuvi/Minjuvi for relapsed or refractory diffuse large B-cell lymphoma, Opzelura cream for atopic dermatitis and vitiligo, Iclusig for chronic myeloid leukemia, Zynyz for metastatic or recurrent locally advanced Merkel cell carcinoma, and Niktimvo for treating chronic graft-versus-host disease. Incyte also has a robust pipeline of clinical-stage products for various cancers and systemic immune and neuro-immune disorders.
INCY’s Geographic footprint
Incyte is a multinational company headquartered in Wilmington, Delaware, with manufacturing and R&D locations across North America, Europe, and Asia. The company established its European headquarters in Morges, Switzerland, in 2021 and has offices in several European countries, including Germany, Italy, Japan, the Netherlands, Spain, Sweden, and the United Kingdom. In May 2024, Incyte expanded its Delaware footprint by acquiring two new buildings in downtown Wilmington to consolidate its U.S. commercial and medical affairs teams.
INCY Corporate Image Assessment
Incyte's brand reputation is built on its commitment to strong science and relentless pursuit of R&D excellence to find new solutions for patients, particularly in rare and hard-to-treat diseases. The company emphasizes its focus on innovation and its positive impact on people's lives through research. In the past year, Incyte has continued to expand its portfolio with additional FDA approvals, such as Opzelura for children with atopic dermatitis. The company's consistent revenue growth, with 2024 seeing a 15% year-over-year growth and Jakafi contributing significantly, also positively reflects on its market position and product efficacy. There were no specific negative events impacting Incyte's brand reputation found in the past year.
Ownership
Incyte Corporation's ownership structure is a mix of institutional, insider, and retail investors. Approximately 49.82% of the company's stock is owned by institutional investors, 15.70% by insiders, and 34.48% by public companies and individual investors. Other sources indicate institutional ownership at around 84% or 96.97%, holding a total of 229,472,556 shares. Major institutional owners include Baker Bros. Advisors Lp, Vanguard Group Inc, BlackRock, Inc., Dodge & Cox, State Street Corp, Aqr Capital Management Llc, Geode Capital Management, Llc, and Renaissance Technologies LLC. Felix Baker is noted as owning the most shares of Incyte Corp among individual investors.
Ask Our Expert AI Analyst
Price Chart
$85.96